New York Fines Endo For Falsely Advertising Opioid Opana ER As Crush Resistant

On March 3, 2016, the New York Attorney General (AG) announced that Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. agreed to pay a fine of $200,000 to settle the AG’s allegation that Endo falsely advertised the opioid pain medication Opana ER as crush resistant. The agreement requires Endo to cease all misrepresentations regarding the properties of Opana ER and to describe accurately the risk of addiction to Opana ER.

The AG had launched an investigation of Endo, focusing on Opana ER, as a result of concerns regarding the role of Opana ER in the larger opioid abuse . . .